31 results on '"McInnes I"'
Search Results
2. OP0207 LIPOSOMAL ANTAGOMIR-155-5P RESTORES ANTI-INFLAMMATORY MACROPHAGES AND IMPROVES ARTHRITIS IN PRE-CLINICAL MODELS OF RHEUMATOID ARTHRITIS
3. AB1082 EARLY CLINICAL RESPONSE AS A PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS AND TNFI-IR RECEIVING GUSELKUMAB (COSMOS)
4. POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
5. OP0122 MACHINE-LEARNING-ASSISTED ANALYSIS IDENTIFIES DISCRETE PHOSPHORYLATION SIGNATURES IN T AND B LYMPHOCYTES ASSOCIATED WITH EARLY RHEUMATOID ARTHRITIS
6. POS1527 EFFECTS OF APREMILAST ON CHANGES IN CARDIOMETABOLIC PARAMETERS BY DIABETES AND OBESITY STATUS IN PATIENTS WITH PSORIATIC ARTHRITIS
7. AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY
8. AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
9. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
10. POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL
11. AB1093 LONG-TERM IMPROVEMENT IN INDIVIDUAL ACR RESPONSE CRITERIA AND RESIDUAL DISEASE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST HOC ANALYSIS OF A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
12. AB1095 IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB
13. POS0027 INDIVIDUAL ENTHESEAL POINTS HAVE DIFFERENTIAL FREQUENCY OF INVOLVEMENT AND IMPACT ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
14. AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
15. OP0007 INCIDENCE, PREVALENCE AND CO-OCCURRENCE OF AUTOIMMUNE DISORDERS, TRENDS OVER TIME AND BY AGE, SEX AND SOCIOECONOMIC STATUS. A POPULATION-BASED STUDY IN 22 MILLION INDIVIDUALS.
16. POS1531 GUSELKUMAB, AN IL-23P19 SUBUNIT–SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64+ MYELOID CELLS AND POTENTLY NEUTRALISES IL-23 PRODUCED FROM THE SAME CELLS
17. OP0130 ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRE-CLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIAL
18. AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
19. P258 ASTERIX: Adaptive stratification of COVID19 to facilitate endotype-directed intervention studies
20. P141 Differential DNA methylation in peripheral naÏve CD4+T-cells in early rheumatoid arthritis patients
21. OP0269 Activation of mertk+cd206+ subpopulation of human synovial tissue-resident macrophages limits inflammatory response
22. AB0927 Probability and impact of achieving low disease activity or remission in patients with psoriatic arthritis treated with apremilast: pooled analysis of the palace 1–3 phase 3 trials
23. SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
24. SAT0271 Secukinumab, a fully human anti-interleukin-17a monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52-week treatment period
25. SAT0468 Presence of poor prognostic factors may predict response to abatacept in patients with active psoriatic arthritis: results from a post hoc analysis from a phase iii study
26. AB0281 Characterization of changes in lymphocyte subsets in baricitinib-treated patients with early, dmard naÏve, rheumatoid arthritis in a phase 3 study
27. THU0111 Novel autoantibody profiles in rheumatoid arthritis and their association with radiographic progression in the scottish early rheumatoid arthritis inception cohort and biobank (SERA)
28. FRI0088 Synovial pathobiology correlates with diagnostic subgroups in early inflammatory arthritis: results from the pathobiology of early arthritis cohort (PEAC)
29. THU0100 In early inflammatory arthritis a lymphoid pathotype signficantly associates with requirement for biologic therapy at 12 months follow up: results from the pathobiology of early arthritis cohort (PEAC)
30. SAT0480 Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal phase 3 clinical trial data
31. SAT0453 Efficacy of ustekinumab in psoriatic arthritis patients by prior treatment exposure and disease duration: data from psummit 1 and psummit 2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.